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Selective suppression of inhibitory synaptic transmission by
nocistatin in the rat spinal cord dorsal horn
Abstract
Nociceptin/orphanin FQ (N/OFQ) and nocistatin (NST) are two recently identified neuropeptides with
opposing effects on several CNS functions, including spinal nociception. The cellular mechanisms that
underlie this antagonism are not known. Here, we have investigated the effects of both peptides on
synaptic transmission mediated by the three fast neurotransmitters l-glutamate, glycine, and GABA in
the superficial layers of the rat spinal cord horn, which constitute the first important site of integration of
nociceptive information in the pain pathway. NST selectively reduced transmitter release from
inhibitory interneurons via a presynaptic Bordetella pertussis toxin-sensitive mechanism but left
excitatory glutamatergic transmission unaffected. In contrast, N/OFQ only inhibited excitatory
transmission. In the rat formalin test, an animal model of tonic pain in which N/OFQ exerts
antinociceptive activity, NST induced profound hyperalgesia after intrathecal application. Similar to
glycine and GABA(A) receptor antagonists, NST had no significant effects in the rat tail-flick test, a
model of acute thermal pain. Our results provide a cellular basis for the antagonism of N/OFQ and NST
and suggest the existence of a so far unidentified membrane receptor for NST. In addition, they support
a role of NST as an endogenous inhibitor of glycinergic and GABAergic neurotransmission in the
sensory part of the spinal cord and as a mediator of spinal hyperalgesia.
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Nociceptin/orphanin FQ (N/OFQ) and nocistatin (NST) are two
recently identified neuropeptides with opposing effects on sev-
eral CNS functions, including spinal nociception. The cellular
mechanisms that underlie this antagonism are not known. Here,
we have investigated the effects of both peptides on synaptic
transmission mediated by the three fast neurotransmitters
L-glutamate, glycine, and GABA in the superficial layers of the
rat spinal cord horn, which constitute the first important site of
integration of nociceptive information in the pain pathway. NST
selectively reduced transmitter release from inhibitory interneu-
rons via a presynaptic Bordetella pertussis toxin-sensitive
mechanism but left excitatory glutamatergic transmission un-
affected. In contrast, N/OFQ only inhibited excitatory transmis-
sion. In the rat formalin test, an animal model of tonic pain in
which N/OFQ exerts antinociceptive activity, NST induced pro-
found hyperalgesia after intrathecal application. Similar to gly-
cine and GABAA receptor antagonists, NST had no significant
effects in the rat tail-flick test, a model of acute thermal pain.
Our results provide a cellular basis for the antagonism of
N/OFQ and NST and suggest the existence of a so far uniden-
tified membrane receptor for NST. In addition, they support a
role of NST as an endogenous inhibitor of glycinergic and
GABAergic neurotransmission in the sensory part of the spinal
cord and as a mediator of spinal hyperalgesia.
Key words: nociceptin/orphanin FQ; nocistatin; nociception;
pain; hyperalgesia; synaptic transmission; spinal cord slice
Hyperalgesia, i.e., an increased sensitivity of noxious stimuli, and
allodynia, i.e., a painful sensation of otherwise innocuous stimuli,
often accompany chronic pain states seen after prolonged tissue
damage. Nociceptin (Meunier et al., 1995), also called orphanin
FQ (Reinscheid et al., 1995), and nocistatin (NST) (Okuda-
Ashitaka et al., 1998) are two recently identified neuropeptides
that have been implicated in the development and/or modulation
of hyperalgesia and allodynia. Nociceptin/orphanin FQ (N/OFQ)
is an endogenous ligand of the opioid receptor-like 1 receptor
(Mollereau et al., 1994), which is now also called N/OFQ recep-
tor. This receptor shares ;60% homology with classical opioid
receptors and is negatively coupled to adenylate cyclase via in-
hibitory G-proteins, but unlike the m, k, and d opioid receptors, it
does not bind classical opioids.
Like other neuropeptides and peptide hormones, N/OFQ is
proteolytically released from a larger precursor protein, called
preproN/OFQ (Saito et al., 1995; Houtani et al., 1996; Nothacker
et al., 1996; Pan et al., 1996). In addition to the cleavage sites
necessary for release of N/OFQ, preproN/OFQ contains several
other potential cleavage sites, i.e., pairs of the basic amino acids
lysine and arginine. Depending on the species, preproN/OFQ
contains three or four putative neuropeptides in addition to
N/OFQ. At least for one of these peptides, the bovine 17 amino
acid peptide b-PNP-3, or bovine nocistatin (bNST), biological
activity has been demonstrated (Okuda-Ashitaka et al., 1998).
bNST has been detected in the CSF of bovines and, when applied
to mice intrathecally, reversed N/OFQ- or prostaglandin E2
(PGE2)-induced hyperalgesia and allodynia via a so far unknown
mechanism. Biological activity has also been demonstrated for
the mouse (Okuda-Ashitaka et al., 1998) and meanwhile for the
human homolog of bNST (Minami et al., 1998). These results
suggest that preproN/OFQ contains at least two biologically ac-
tive peptides, which appear to affect spinal nociception and pos-
sibly other CNS functions in opposite directions. So far, nothing
is known about the cellular mechanisms that underlie these
opposing effects. Here, we have investigated the effects of N/OFQ
and NST on excitatory and inhibitory neurotransmission in the
superficial layers of the rat spinal cord dorsal horn, which consti-
tutes the first site of synaptic integration of nociceptive informa-
tion (Yaksh and Malmberg, 1994). We demonstrate that NST
reduces inhibitory glycinergic and GABAergic synaptic transmis-
sion but leaves excitatory glutamatergic transmission unaffected,
whereas N/OFQ only interferes with glutamatergic transmission.
MATERIALS AND METHODS
Slice preparation and electrophysiolog ical recordings. Ten- to 16-d-old
Sprague Dawley rats of either sex were killed under ether narcosis by
decapitation. Transverse slices (250-mm-thick) of the lumbar spinal cord
were prepared as described previously (Liebel et al., 1997). Whole-cell
patch-clamp recordings were performed from neurons identified under
visual control using the infrared gradient contrast technique coupled to
a video microscopy system (Dodt and Zieglga¨nsberger, 1994). Slices were
completely submerged and continuously superfused with external solu-
tion, which contained (in mM): 125 NaCl, 26 NaHCO3, 1.25 NaH2PO4,
2.5 KCl, 2 CaCl2, 1 MgCl2, and 10 glucose, pH 7.30 (315 mOsm/l),
bubbled with 95% O2–5% CO2. Patch pipettes (4–5 MV) were filled with
internal solution containing (in mM): 130 K-gluconate, 20 KCl, 2 MgCl2,
0.05 EGTA, 3 Na-ATP, 0.1 Na-GTP, and 10 Na-HEPES, pH 7.30.
QX-314 (5 mM) was added to the internal solution to block voltage-
activated sodium currents. EPSCs and IPSCs were evoked at a frequency
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of 0.1–0.07 Hz and recorded at a holding potential of 280 mV at room
temperature. Short hyperpolarizing voltage steps to 290 mV were ap-
plied every minute to monitor input and access resistance. EPSCs were
elicited by ipsilateral extracellular electrical stimulation (100 msec, 3–10
V) of the dorsal root entry zone using a glass electrode filled with 1 M
NaCl. To record IPSCs, the stimulation electrode was placed ;50 mm
away from the recorded neuron. Peptide or drug-containing solutions
were applied by bath perfusion at a rate of 1–2 ml/min. Percent inhibi-
tion of PSCs by the neuropeptides was determined from the average
amplitude of 10 consecutive PSCs evoked immediately before application
of the peptides and when a steady state of inhibition was reached, usually
;3 min after application. In some experiments, a cocktail of protease
inhibitors (Complete mini, EDTA-free; Roche Diagnostics, Mannheim,
Germany) was added to the external solution. Spontaneously occurring
mIPSCs were recorded in the presence of tetrodotoxin (TTX) (1 mM).
Amplitude and frequency distributions were analyzed using a custom-
made Igor macro (Liebel et al., 1997).
Pertussis toxin treatment. Treatment with pertussis toxin (PTX) was
performed similar to the method described by Meis and Pape (1998). In
brief, slices prepared as described above were incubated in 35 mm tissue
culture dishes filled with 2 ml of Eagle’s basal medium supplemented
with 50% HBSS, 50% horse serum, 2 mM glutamine, and 0.65%
D-glucose, in a standard tissue culture incubator at 34°C, 5% CO2–95%
air for 14–18 hr. PTX (500 ng/ml) (Calbiochem, La Jolla, CA) or vehicle
(NaCl) was added to PTX-treated and control slices, respectively. Apart
from that, incubation conditions of PTX-treated slices and control slices
were identical. PTX-treated slices and control slices were recorded
alternately.
Behavioral testing. The pronociceptive and/or antinociceptive effects of
rat NST consisting of the 17 C-terminal amino acids (rNST1–17) were
analyzed in the rat formalin test (Dubuisson and Dennis, 1977) and the
tail-flick test. Experiments were performed at room temperature.
Sprague Dawley rats weighing 350–400 gm were anesthetized with
ketamine (100 mg/kg, i.p.) and xylacine (5 mg/kg, i.p.) and implanted
with polyethylene catheters (inner diameter of 0.28 mm, outer diameter
of 0.61 mm), which were extended from the cisterna to the rostral edge
of the lumbar enlargement. Only rats with unimpaired motor function
were used. Formalin tests and tail-flick tests were performed 6–10 d after
implantation. Rats were randomly assigned to the different treatment
groups consisting of four to six rats each. rNST or vehicle (0.9% NaCl) were
delivered to the spinal cord via the catheters in a total volume of 10 ml.
In the formalin tests, formalin (50 ml, 5%) was injected subcutaneously
into the dorsal surface of the left hind paw 10 min after intrathecal
injection of rNST or vehicle. Flinches of the injected paw were counted
at 1 min intervals for 60 min starting 10 min after intrathecal injection.
Tail-flick latencies (TFL) were determined using an electronically con-
trolled algesiometer (Ugo Basile, Comerio-Varese, Italy). During mea-
surements of TFL, rats were kept in a plastic restrainer. TFL were
determined 20, 40, and 60 min before intrathecal injection and every 10
min for 1 hr after intrathecal injection. Cutoff time was set to 15 sec to
avoid unnecessary tissue damage. After the tests, rats were killed by CO2
inhalation, and proper position of the catheter tip was visually verified
after laminectomy and methylene blue injection.
All behavioral tests and the killing of the animals were performed in
accordance with the institutional guidelines of the University of
Erlangen-Nu¨rnberg and with the Society for Neuroscience.
Peptides. rNST1–35 (rat preproN/OFQ 98–132) was from Phoenix
Pharmaceuticals (Mountain View, CA); its C-terminal 17 amino acid
peptide (rNST1–17, rat preproN/OFQ 116–132) was obtained from Dr.
M. Herkert (Institut f u¨r Biochemie, Universita¨t Erlangen, Erlangen,
Germany) and from Research Genetics (Huntsville, AL); bNST was from
Tocris Cookson (Bristol, UK); and N/OFQ was purchased from Dr. M.
Herkert and from Tocris Cookson. Peptides (purity .95%) were dis-
solved in external recording solution and stored in aliquots (1 mM) at
220°C. Fresh dilutions were made with standard external solution on
every experimental day.
Figure 1. Effects of NST on inhibitory synaptic transmission in rat dorsal
horn neurons. A, Averages of 10 consecutively recorded IPSCs under
control condition (control ), in the presence of rNST1–17 (rNST; 10 mM),
and after removal of rNST1–17 (wash). B, Concentration–response curves
of rNST1–17 (solid line) and rNST1–35 and bNST (both dashed lines).
Ordinate, Effect of NST on IPSC amplitudes expressed as relative re-
maining amplitude. Abscissa, NST concentration on a logarithmic scale.
Data points were fitted to the following equation: y 5 ymax 2 [( ymax 2
ymin )/(1 1 (IC50 /C)
nH)]. ymax is the normalized IPSC amplitude under
control conditions, ymin is the relative IPSC amplitude in the presence of
saturating concentrations of NST, C is the NST concentration, IC50 is the
half-maximum effective concentration, and nH is the Hill coefficient.
rNST1–17 (F): average maximum inhibition, 45.7 6 3.3%; IC50 , 486 6
129 nM; nH , 1.44 6 0.59. rNST1–35 (f): IC50 , 863 6 242 nM. bNST (M):
IC50 , 979 6 347 nM. Inhibition was statistically significant ( p 5 0.05) for
all concentrations of rNST1–17 ($500 nM) (ANOVA followed by a
Bonferroni post hoc test). n, Number of cells was 5–20 for each peptide
and each concentration.
Figure 2. Involvement of PTX-sensitive G-proteins. A, Averages of 10
consecutive IPSCs recorded under control conditions or in the presence
of rNST1–17 (10 mM). Incubation with PTX (500 ng/ml, 14–18 hr)
completely suppressed the effect of rNST1–17 (right), whereas incubation
with vehicle had no effect (lef t). B, Normalized IPSC amplitudes versus
time from six PTX-treated (F) and four control (E) slices.
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RESULTS
The rat homolog of bNST is a 35 amino acid neuropeptide, of
which the C-terminal eight amino acids are conserved among
mice and rats and are crucial for biological activity (Okuda-
Ashitaka et al., 1998). We have used a peptide consisting of the 17
C-terminal amino acids (rNST1–17) to investigate the effects of
rNST on neurotransmission in the spinal cord mediated by the
three major fast neurotransmitters L-glutamate, glycine, and
GABA. PSCs were evoked by extracellular electrical stimulation
and recorded in the whole-cell configuration of the patch-clamp
technique from neurons in the superficial layers (substantia ge-
latinosa) of the spinal cord dorsal horn in which thin and unmy-
elinated (nociceptive) nerve fibers terminate (Willis et al., 1995).
IPSCs were recorded in isolation after blockade of EPSCs with
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (10 mM) and
D(2)-2-amino-5-phosphonovaleric acid (D-APV) (50 mM). IPSCs
typically reversed polarity near 230 mV, which was close to the
chloride equilibrium potential of the recording solutions used.
IPSCs could almost completely be blocked by a combination of
bicuculline and strychnine, indicating that they were mediated by
glycine and/or GABAA receptors.
At saturating concentrations ($1 mM), rNST1–17 reversibly
decreased the amplitudes of IPSCs by ;50% (Fig. 1A) but had no
effect on excitatory synaptic transmission (compare with Fig. 5).
Inhibition occurred in a concentration-dependent manner with
half-maximum effective concentration in the submicromolar
range. Experiments performed with the complete rat homolog of
NST (rNST1–35) and with bNST yielded similar results. Both
peptides reduced IPSCs with the same efficacy as rNST1–17 but
were slightly less potent (Fig. 1B). Several experiments were
performed in the presence of protease inhibitors (for details, see
Materials and Methods) to exclude the possibility that significant
amounts of the peptide were degraded by proteases in the spinal
cord tissue. Inhibition of IPSCs was compared in the presence
and absence of protease inhibitors at the lowest effective concen-
tration of rNST1–17 (100 nM) at which the effect of protease
inhibition should be most striking. However, inhibition was nearly
identical under both conditions (6.2 6 4.6 vs 5.4 6 5.0%; number
of cells, n 5 5 each). This result also argues against the possibility
that the effects observed were mediated by degradation products
of rNST1–17 rather than by rNST1–17 itself.
Most neuropeptides exert their action via the activation of
seven transmembrane receptors coupled to GTP binding proteins
(G-proteins) (Strand, 1999). We tested for a possible involvement
of G-proteins of the Gi/Go type using PTX, a selective inhibitor
of these G-proteins (Hille, 1994). Overnight incubation of the
slices with PTX (500 ng/ml) had no effect on baseline synaptic
transmission. In the absence of rNST1–17, IPSC amplitudes were
similar in control slices and PTX-treated slices (409 6 130 pA,
mean 6 SEM, n 5 6; vs 461 6 198 pA, n 5 4). However, the
inhibitory effect of rNST1–17 was completely prevented by PTX
treatment. The average reduction of IPSC amplitudes by
rNST1–17 (10 mM) was 5.6 6 3.7% (n 5 6) in PTX-treated slices
compared with 32.5 6 8.6% (n 5 4) in control slices (Fig. 2).
Because inhibitory neurotransmission in the rat spinal cord is
mediated by both glycine and GABA (Grudt and Henderson,
1998), we have investigated the effects of rNST1–17 on the
GABAergic and glycinergic transmission separately. As shown in
Figure 3, A and B, rNST1–17 suppressed glycinergic and
GABAergic components of IPSCs almost equally (glycinergic
component, 48.8 6 6.2%, n 5 14; GABAergic component, 49.9 6
6.9%, n 5 8).
To determine the site of action of rNST1–17, we have used two
different methods. First, changes in the coefficient of variation of
IPSC amplitudes were analyzed (Malinow and Tsien, 1990; Jonas
Figure 3. Variation analysis indicates a presynaptic site of rNST action.
A, B, Changes in the coefficient of variation of IPSC amplitudes were
analyzed for the glycinergic (A) and GABAergic (B) component of
inhibitory synaptic transmission. The GABAergic and glycinergic IPSC
components were isolated with strychnine (300 nM) and bicuculline (10
mM), respectively. Left, Current traces averaged from 20 consecutive
stimulations under control conditions (control ) and in the presence of
rNST1–17 (10 mM). At least 20 IPSCs were recorded under control
conditions and after reaching a steady-state degree of inhibition. Right,
Complete time course of representative experiments. C, The coefficient of
variation to the (22) power of the IPSC amplitudes in the presence of
rNST1–17 (rNST; 10 mM) (CV22rNST) was plotted against the average
amplitude in the presence of rNST1–17 (IPSC amplituderNST) both nor-
malized to the respective control values (CV22con and IPSC amplitude-
con). F, Glycinergic component; V, GABAergic component. Data points
for both components were close to the identity line, indicting a presyn-
aptic site of action.
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et al., 1998). A plot of the coefficient of variation to the (22)
power versus the average IPSC amplitude both normalized to the
respective control value shows that the data points were all close
to unity, which indicates a presynaptic rather than a postsynaptic
site of action (Fig. 3B).
Additional evidence against a postsynaptic site of action was
obtained from the analysis of spontaneously occurring miniature
IPSCs (mIPSCs), which were recorded in the presence of TTX
(1 mM). rNST1–17 had no effect on the amplitude distribution of
these mIPSCs, indicating that it did not act postsynaptically by
modulating GABAA or glycine receptor function (Fig. 4). This is
in line with our observation that currents elicited by exogenous
application of GABA or glycine were not affected by rNST1–17
(10 mM; data not shown). In this context, it is interesting to note
that no change in input resistance was observed when rNST1–17
(10 mM) was applied (DRmem, 0.8 6 6.4%; n 5 28), which also
argues against the possibility that rNST1–17 opens postsynaptic
G-protein-activated potassium channels in spinal cord dorsal
horn neurons. In contrast to what one would expect for a presyn-
aptic site of action, no decrease in the frequency of mIPSCs was
found. Instead, mIPSC frequency slightly increased in five of
seven recordings (Fig. 4E). This increase was statistically not
significant ( p 5 0.242; paired Student’s t test) and did not corre-
late with the application of rNST1–17. It might rather reflect a
slight gradual increase in mIPSC frequency, which was sometimes
observed in our recordings.
We have next compared the effects of rNST1–17 on EPSCs and
IPSCs with those of N/OFQ. IPSCs were isolated as described
above. EPSCs were recorded in the presence of bicuculline (10
mM) and strychnine (2 mM). They were almost completely blocked
by CNQX (10 mM) and D-APV (50 mM), indicating that they were
mediated by ionotropic glutamate receptors. In these experi-
ments, all neurons tested were exposed to both peptides consec-
utively (Fig. 5). Again, average IPSC amplitudes were signifi-
cantly reduced to 59.5 6 2.7% by rNST1–17 (10 mM) but
remained unaffected (98.5 6 1.9%; n 5 10) after application of
N/OFQ (10 mM) (Fig. 5A). In contrast, EPSCs were insensitive to
application of rNST1–17 at concentrations up to 10 mM. The
average EPSC amplitude was 102.3 6 1.2% of the control ampli-
tude (n 5 14) (Fig. 5B). However, a reversible decrease in the
amplitudes of EPSCs to 57 6 3.2% (n 5 14) was observed after
application of N/OFQ (10 mM). Thus, rNST1–17 turned out to be
a specific inhibitor of inhibitory synaptic transmission, whereas
N/OFQ selectively interfered with excitatory transmission.
To test for the relevance of these actions for spinal nociception,
we investigated the effects of rNST1–17 in the rat formalin test
and the tail-flick test, which are differentially sensitive to changes
in the strength of inhibitory synaptic transmission (Yaksh and
Malmberg, 1994). In the rat formalin test, a typical biphasic
reaction was observed in both control and rNST1–17-treated rats.
When applied to the subarachnoid space of the lumbar spinal
cord via a surgically implanted catheter (i.e., intrathecally),
rNST1–17 dose-dependently increased the number of flinches
during all three phases of the test at doses ranging from 1
pmol/rat to 10 nmol/rat (Fig. 6A). Statistically significant hyper-
algesia was achieved at a dose of 10 nmol/rat for all phases. At
lower doses, the effect was most prominent during phase IIa (Fig.
6B). In the tail-flick test, an animal model of acute thermal pain,
only a small and statistically not significant decrease in TFL was
found after intrathecal injection of rNST1–17 (Fig. 6C).
DISCUSSION
The recently discovered neuropeptide NST has originally been
described as a functional antagonist of N/OFQ- and PGE2-
induced hyperalgesia (Okuda-Ashitaka et al., 1998). Our results
indicate that NST has per se biological activity. It specifically
suppresses transmitter release from inhibitory (GABAergic and
glycinergic) interneurons in the rat spinal cord dorsal horn.
Thereby, it serves as a functional antagonist of N/OFQ, which
inhibits excitatory (glutamatergic) synaptic transmission. Because
neurons in the substantia gelatinosa do not represent a homoge-
neous group, recordings were probably made from different cell
types that cannot be easily distinguished on electrophysiological
or morphological criteria in a vital unstained slice preparation.
Despite this heterogeneity, the effects of NST and N/OFQ on
transmitter release were very reliably observed, suggesting that
Figure 4. rNST has no effect on spon-
taneously occurring miniature IPSCs.
A, Spontaneously occurring mIPSCs
recorded in the presence of TTX
(1 mM) at a holding potential of 280
mV. B, Normalized amplitude histo-
grams of mIPCs recorded under con-
trol conditions (lef t) and in the pres-
ence of rNST (right) obtained from the
same cell. Left trace in each histogram
shows the amplitude distribution of
the current noise. Insets show mIPSC
averaged from 25 consecutive events.
C, Changes in the median mIPSC am-
plitude in eight neurons. D, Normal-
ized cumulative amplitude histograms
derived from eight experiments. E,
Changes in the average frequency of
mIPSCs.
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they represent a widespread phenomenon in the substantia
gelatinosa.
Our results suggest a so far unknown membrane receptor to
which NST binds in the spinal cord dorsal horn. The sensitivity to
PTX of rNST1–17-mediated suppression of inhibitory neuro-
transmission indicates that this putative NST receptor couples to
GTP binding proteins of the Gi/Go type and presumably belongs
to the large group of membrane receptors with seven transmem-
brane domains. The presynaptic nature of the suppression of
inhibitory neurotransmission by NST and the lack of impairment
of motor function in the behavioral pharmacology tests suggest
that, in the spinal cord, the putative NST receptor is preferen-
tially expressed in dorsal horn inhibitory interneurons.
Well established mechanisms involved in the modulation of
transmitter release include the activation or facilitation of potas-
sium channels and the inhibition of voltage-gated Ca21 channels.
In most CNS regions, including the spinal cord, action potential-
evoked Ca21 influx into presynaptic nerve terminals and trans-
mitter release are mediated primarily by N- and/or P/Q-type
Ca 21 channels (Takahashi and Momiyama, 1993). NST may thus
reduce action potential-triggered GABA and glycine release via
inhibition of N- and P/Q-type Ca21 channels, which are well
known targets of a variety of G-protein-coupled receptors (Zam-
poni and Snutch, 1998). These Ca21 channels are closed at the
resting potential of the cell and hence are of only minor relevance
for spontaneous transmitter release (Bao et al., 1998). This may
explain why rNST1–17 reduced action potential-evoked GABA
and glycine release but did not decrease the frequency of mIP-
SCs. Alternative mechanisms by which NST might suppress in-
hibitory synaptic transmission include the opening G-protein-
activated potassium channels or an interaction with the vesicle
fusion apparatus (Jarolimek and Misgeld, 1997). However, these
possibilities appear less likely. Activation of potassium channels
should change membrane resistance, which remained constant
when rNST1–17 was applied, and a direct interference with the
release process should decrease spontaneous transmitter release,
which also not observed in our experiments.
Much attention has been focused on glutamatergic synaptic
transmission in the spinal cord dorsal horn (for review, see Yaksh
et al., 1999). Facilitation of glutamatergic transmission has been
proposed as a mechanism of activity-dependent generation of
chronic of pain (Zieglga¨nsberger and To¨lle, 1993), and its inhi-
bition is generally accepted as an important target for the anal-
gesic action of opioid peptides. Less is known about the func-
tional significance of endogenous modulators of glycinergic and
GABAergic synaptic transmission for spinal nociception. Al-
though the predominant effects of blockers of inhibitory neuro-
transmission, e.g., of strychnine and picrotoxin, are convulsions,
there is considerable evidence that glycine and/or GABA are also
involved in sensory information processing. Glycine and GABAA
receptor antagonists increase the size of receptive fields of dorsal
horn neurons (Zieglga¨nsberger and Herz, 1971). Strychnine in-
toxication in humans (Arena, 1979) and strychnine- or
bicuculline-treatment of mice (Yaksh and Rudy, 1977) are char-
acterized by a hypersensitivity to mechanical stimulation. The
spastic mouse mutant, which has a strongly reduced number of
functional glycine receptors (Becker et al., 1986), is particularly
sensitive to mechanical stimulation (White and Heller, 1982). The
encoding of low-threshold mechanical stimulation as innocuous is
thought to depend on the presence of tonic inhibition by glycin-
ergic and GABAergic interneurons (Yaksh and Malmberg, 1994).
Suppression of inhibitory interneurons, which are located be-
tween primary afferent low-threshold mechanoreceptors and cen-
trally projecting wide dynamic range neurons (Carlton and
Hayes, 1990; Hayes and Carlton, 1992), would then result in pain
or pain-related reactions to otherwise innocuous stimuli (Yaksh
Figure 5. Inhibition of EPSCs and IPSCs
by N/OFQ and rNST. A, B, IPSCs (A) and
EPSCs (B) were recorded in the presence
of CNQX (10 mM) and D-APV (20 mM) or
of bicuculline (10 mM) and strychnine (2
mM), respectively. Top, Current traces are
averages of 10 consecutive traces each, re-
corded under control conditions, in the
presence of N/OFQ or in the presence of
rNST1–17 (both 10 mM) and after removal
of the peptides (wash). Middle, Complete
time course of representative experiments.
Bottom, Changes in the average IPSC and
EPSC amplitudes in individual cells (A,
n 5 9; B, n 5 14) during application of
N/OFQ and rNST1–17 (both 10 mM) and
after removal of the peptides, all normal-
ized to the respective control amplitudes.
Bars represent the average PSC amplitudes
(blue, N/OFQ; red, r-NST1–17). Note that
the order of N/OFQ and rNST1–17 appli-
cation is different in A and B.
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and Malmberg, 1994). Indeed, NST augmented nociceptive be-
havior in the rat formalin test (this report) and facilitated noci-
ceptive flexor reflexes (Xu et al., 1999) but had only little effect on
acute thermal pain (this report; Yamamoto and Sakashita, 1999).
The effects of NST in the different pain models are therefore
similar to those of postsynaptic blockers of GABAA and glycine
receptors (for review, see Yaksh and Malmberg, 1994). When
injected intrathecally, bicuculline (Kaneko and Hammond, 1997)
and strychnine (Yaksh and Malmberg, 1994) increase nociceptive
behavior in the formalin test but induce only modest changes in
tail-flick latencies (Yaksh and Malmberg, 1994).
On the other hand, GABA released from local interneurons in
the substantia gelatinosa can depolarize primary afferent nerve
terminals (Thompson and Wall, 1996) and thereby augment hy-
peralgesia and inflammation (Sluka et al., 1993). A preferential
reduction of GABA release from these interneurons might ex-
plain the anti-allodynic or analgesic effects seen by others after
injection of NST (Okuda-Ashitaka et al., 1998; Yamamoto and
Sakashita, 1999).
Antinociceptive effects of N/OFQ have been reported repeat-
edly after intrathecal injection in both tonic pain models, e.g., the
rat formalin test (Erb et al., 1997; Yamamoto et al., 1997), and
acute pain models, such as the tail-flick test (Xu et al., 1996; Tian
et al., 1997). In this respect, the pharmacological profile of
N/OFQ resembles that of L-glutamate receptor antagonists.
NMDA receptor blockers reduce nociceptive behavior in the rat
formalin test (Coderre and Melzack, 1992; Yamamoto and
Yaksh, 1992; Chaplan et al., 1997), and inhibition of AMPA
receptors has been demonstrated to increase latencies in the
tail-flick test (Na¨sstro¨m et al., 1992; Lutfy et al., 1997). Inhibition
of L-glutamate release by N/OFQ in the spinal cord dorsal horn in
which L-glutamate is the dominant fast excitatory neurotransmit-
ter might thus very well underlie the antinociceptive effects of
spinal N/OFQ. On the other hand, extrapolation of cellular data
obtained from young rats to nociceptive behavior in adult animals
must be done with caution. There is considerable evidence that
significant changes occur in the primary afferent input to substan-
tia gelatinosa neurons during postnatal development. Within the
first 8 weeks after birth, low-threshold mechanoreceptors (Ab
fibers) retract from the substantia gelatinosa, and Ad and C fiber
input dominates in mature animals (Fitzgerald et al., 1994; Park
et al., 1999).
The physiological role of N/OFQ has been addressed with the
use of mutant mice lacking the N/OFQ receptor (Nishi et al.,
1997). Although these animals showed several behavioral abnor-
malities, no alteration in nociceptive thresholds was detected. It
is, however, interesting to note that these mice differed from
those with a disrupted preproN/OFQ gene in as much as the latter
mice exhibited increased nociceptive thresholds (Ko¨ster et al.,
1999). This difference might be explained by the lack not only of
N/OFQ but also of other preproN/OFQ-derived neuropeptides,
including NST.
N/OFQ and NST are derived from the same precursor peptide,
preproN/OFQ, which in the spinal cord dorsal horn is mainly
expressed in local interneurons (Riedl et al., 1996; Neal et al.,
1999). Because both N/OFQ (Liebel et al., 1997) and NST act at
least in part via a presynaptic site, our results suggest that N/OFQ
and NST are released from such local interneurons onto the
presynaptic terminals of excitatory and inhibitory neurons. It is at
present not known under what physiological or pathophysiologi-
cal conditions these peptides are released and whether they are
always coreleased. There is evidence from other neuropeptide or
hormone precursors, such as proopiomelanocortin, that post-
translational modifications, peptide sorting, and secretion can
occur in a peptide-specific manner (Strand, 1999). Such post-
translational modifications can be tissue-specific and may be un-
der control of certain stimuli. A group of enzymes called sortases
can intracellularly bind certain hormones (e.g., prolactin, insulin,
and human growth factor) and prevent them thereby from storage
and secretion (Chung et al., 1989). Different peptides may be
transported to different secretory vesicles enabling differential
Figure 6. Effects of rNST in the rat formalin test and the tail-flick test. A,
B, Rat formalin test. Flinches were counted starting 10 min after intra-
thecal administration of rNST in 1 min intervals over a period of 60 min.
A, Number of flinched per minute (mean 6 SEM). F, Vehicle; E,
rNST1–17, 10 nmol/rat; M, rNST1–17, 0.1 nmol/rat; , rNST1–17 0.001
nmol/rat. B, Bars show number of flinches per minute (mean 6 SEM)
averaged during phase I (0–10 min), phase IIa (20–39 min), and phase IIb
(40–60 min) under control conditions and after application of different
doses of rNST. Statistically significant mean difference versus respective
control (*p # 0.05; **p # 0.01; n 5 4–6; ANOVA followed by Scheffe´ post
hoc test). Experiments with rNST1–35 (10 nmol/rat) yielded similar
results. C, Tail-flick latencies (mean 6 SEM) were determined under
control conditions (baseline, averaged from measurements taken 20, 40,
and 60 min before intrathecal injection) and every 10 min after intrathecal
injection. F, Vehicle; E, rNST1–17, 10 nmol/rat; M, rNST1–17, 1 nmol/
rat; , rNST1–17, 0.1 nmol/rat (differences between the treatment groups
were not significant at all time points; n 5 5–6; ANOVA).
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and controlled release (Fumagalli and Zanini, 1985). It appears
therefore possible that, under certain conditions, the production
and/or release of N/OFQ and NST are differentially regulated.
In summary, we have shown that NST inhibits GABAergic and
glycinergic neurotransmission in the spinal cord dorsal horn via a
presynaptic mechanism involving PTX-sensitive G-proteins. This
effect provides a cellular mechanism for the hyperalgesic action of
this peptide observed after spinal application. In concert with
N/OFQ, NST presents as a modulatory machinery capable of
tuning the spinal nociceptive system to states of both increased
and decreased sensitivity to painful stimuli. Inhibition by NST of
synaptic release of GABA and glycine in other areas of the CNS,
including the hippocampus, may account for other effects of NST,
including those on learning and memory (Nicol et al., 1998;
Hiramatsu and Inoue, 1999).
REFERENCES
Arena JM (1979) Poisoning: toxicity, symptoms, treatments, Ed 4, pp
177–179. Springfield, IL: Thomas.
Bao J, Li JJ, Perl ER (1998) Differences in Ca 21 channels governing
generation of miniature and evoked excitatory synaptic currents in
spinal laminae I and II. J Neurosci 18:8740–8750.
Becker C-M, Hermans-Borgmeyer I, Schmitt B, Betz H (1986) The
glycine receptor deficiency of the mutant mouse spastic. Evidence for
normal glycine receptor structure and localization. J Neurosci
6:1358–1364.
Carlton SM, Hayes ES (1990) Light microscopic and ultrastructural
analysis of GABA-immunoreactive profiles in the monkey spinal cord.
J Comp Neurol 300:162–182.
Chaplan SR, Malmberg AB, Yaksh TL (1997) Efficacy of spinal NMDA
receptor antagonism in formalin hyperalgesia and nerve injury evoked
allodynia in the rat. J Pharmacol Exp Ther 280:829–838.
Chung KN, Walter P, Aponte GW, Moore HP (1989) Molecular sorting
in the secretory pathway. Science 243:192–197.
Coderre TJ, Melzack R (1992) The contribution of excitatory amino
acids to central sensitization and persistent nociception after formalin-
induced tissue injury. J Neurosci 12:3665–3670.
Dodt H-U, Zieglga¨nsberger W (1994) Infrared videomicroscopy: a new
look at neuronal structure and function. Trends Neurosci 17:453–458.
Dubuisson D, Dennis SG (1977) The formalin test: a quantitative study
of the analgesic effects of morphine, meperidine, and brain stem stim-
ulation in rats and cats. Pain 4:161–174.
Erb K, Liebel JT, Tegeder I, Zeilhofer HU, Brune K, Geisslinger G
(1997) Spinally delivered nociceptin/orphanin FQ reduces flinching
behaviour in the rat formalin test. NeuroReport 8:1967–1970.
Fitzgerald M, Butcher T, Shortland P (1994) Developmental changes in
the laminar termination of A fibre cutaneous sensory afferents in the rat
spinal cord dorsal horn. J Comp Neurol 348:225–233.
Fumagalli G, Zanini A (1985) In cow anterior pituitary, growth hor-
mone and prolactin can be packed in separate granules of the same cell.
J Cell Biol 100:2019–2024.
Grudt TJ, Henderson G (1998) Glycine and GABAA receptor-mediated
synaptic transmission in rat substantia gelatinosa: inhibition by mu-
opioid and GABAB agonists. J Physiol (Lond) 507:473–483.
Hayes ES, Carlton SM (1992) Primary afferent interactions: analysis of
calcitonin gene-related peptide-immunoreactive terminals in contact
with unlabeled and GABA-immunoreactive profiles in the monkey
dorsal horn. Neuroscience 47:873–896.
Hille B (1994) Modulation of ion-channel function by G-protein coupled
receptors. Trends Neurosci 17:531–536.
Hiramatsu M, Inoue K (1999) Effects of nocistatin on nociceptin-
induced impairment of learning and memory in mice. Eur J Pharmacol
367:151–155.
Houtani T, Nishi M, Takeshima H, Nukada T, Sugimoto T (1996) Struc-
ture and regional distribution of nociceptin/orphanin FQ precursor.
Biochem Biophys Res Commun 219:714–719.
Jarolimek W, Misgeld U (1997) GABAB receptor-mediated inhibition
of tetrodotoxin-resistant GABA release in rodent hippocampal CA1
pyramidal cells. J Neurosci 17:1025–1032.
Jonas P, Bischofberger J, Sandku¨hler J (1998) Corelease of two fast
neurotransmitters at a central synapse. Science 281:419–424.
Kaneko M, Hammond DL (1997) Role of spinal gamma-aminobutyric
acidA receptors in formalin-induced nociception in the rat. J Pharma-
col Exp Ther 282:928–938.
Ko¨ster A, Montkowski A, Schulz S, Stube EM, Knaudt K, Jenck F,
Moreau JL, Nothacker HP, Civelli O, Reinscheid RK (1999) Targeted
disruption of the orphanin FQ/nociceptin gene increases stress suscep-
tibility and impairs stress adaptation in mice. Proc Natl Acad Sci USA
96:10444–10449.
Liebel JT, Swandulla D, Zeilhofer HU (1997) Modulation of excitatory
synaptic transmission by nociceptin in superficial dorsal horn neurones
of the neonatal rat spinal cord. Br J Pharmacol 123:425–432.
Lutfy K, Cai SX, Woodward RM, Weber E (1997) Antinociceptive
effects of NMDA and non-NMDA receptor antagonists in the tail flick
test in mice. Pain 70:31–40.
Malinow R, Tsien RW (1990) Presynaptic enhancement shown by
whole-cell recordings of long-term potentiation in hippocampal slices.
Nature 346:177–180.
Meis S, Pape HC (1998) Postsynaptic mechanisms underlying respon-
siveness of amygdaloid neurons to nociceptin/orphanin FQ. J Neurosci
18:8133–8144.
Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P,
Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H,
Vassart G, Parmentier M, Costentin J (1995) Isolation and structure
of the endogenous agonist of opioid receptor-like ORL1 receptor.
Nature 377:532–535.
Minami T, Okuda-Ashitaka E, Nishiuchi Y, Kimura T, Tachibana S, Mori
H, Ito S (1998) Anti-nociceptive responses produced by human puta-
tive counterpart of nocistatin. Br J Pharmacol 124:1016–1018.
Mollereau C, Simons MJ, Soularue P, Liners F, Vassart G, Meunier JC,
Parmentier M (1994) ORL1, a novel member of the opioid receptor
family. Cloning, functional expression and localization. FEBS Lett
341:33–38.
Na¨sstro¨m J, Karlsson U, Post C (1992) Antinociceptive actions of dif-
ferent classes of excitatory amino acid receptor antagonists in mice. Eur
J Pharmacol 212:21–29.
Neal Jr CR, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H,
Watson Jr SJ (1999) Localization of orphanin FQ (nociceptin) pep-
tide and messenger RNA in the central nervous system of the rat.
J Comp Neurol 406:503–547.
Nicol B, Lambert DG, Rowbotham DJ, Okuda-Ashitaka E, Ito S, Smart
D, McKnight AT (1998) Nocistatin reverses nociceptin inhibition of
glutamate release from rat brain slices. Eur J Pharmacol 356:R1–R3.
Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi T, Kuno J,
Takeshima H, Nukada T, Nabeshima T, Yamashita T, Noda T, Sugi-
moto T (1997) Unrestrained nociceptive response and disregulation of
hearing ability in mice lacking the nociceptin/orphanin FQ receptor.
EMBO J 16:1858–1864.
Nothacker HP, Reinscheid RK, Mansour A, Henningsen RA, Ardati A,
Monsma Jr FJ, Watson SJ, Civelli O (1996) Primary structure and
tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci
USA 93:8677–8682.
Okuda-Ashitaka E, Minami T, Tachibana S, Yoshihara Y, Nishiuchi Y,
Kimura T, Ito S (1998) Nocistatin, a peptide that blocks nociceptin
action in pain transmission. Nature 392:286–289.
Pan YX, Xu J, Pasternak GW (1996) Cloning and expression of a cDNA
encoding a mouse brain orphanin FQ/nociceptin precursor. Biochem J
315:11–13.
Park JS, Nakatsuka T, Nagata K, Higashi H, Yoshimura M (1999) Re-
organization of the primary afferent termination in the rat spinal dorsal
horn during post-natal development. Brain Res Dev Brain Res
113:29–36.
Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA,
Bunzow JR, Grandy DK, Langen H, Monsma Jr FJ, Civelli O (1995)
Orphanin FQ a neuropeptide that activates an opioid-like G protein-
coupled receptor. Science 270:792–794.
Riedl M, Shuster S, Vulchanova L, Wang J, Loh HH, Elde R (1996)
Orphanin FQ/nociceptin-immunoreactive nerve fibers parallel those
containing endogenous opioids in rat spinal cord. NeuroReport
7:1369–1372.
Saito Y, Maruyama K, Saido TC, Kawashima S (1995) N23K, a gene
transiently up-regulated during neural differentiation, encodes a pre-
cursor protein for a newly identified neuropeptide nociceptin. Biochem
Biophys Res Commun 217:539–545.
Sluka KA, Willis WD, Westlund KN (1993) Joint inflammation and
hyperalgesia are reduced by spinal bicuculline. NeuroReport 5:109–112.
4928 J. Neurosci., July 1, 2000, 20(13):4922–4929 Zeilhofer et al. • Suppression of Spinal IPSCs by Nocistatin
Strand FL (1999) Neuropeptides: regulators of physiological processes,
pp 99–120. Cambridge, MA: MIT.
Takahashi T, Momiyama A (1993) Different types of calcium channels
mediate central synaptic transmission. Nature 366:156–158.
Thompson SW, Wall PD (1996) The effect of GABA and 5-HT receptor
antagonists on rat dorsal root potentials. Neurosci Lett 217:153–156.
Tian JH, Xu W, Fang Y, Mogil JS, Grisel JE, Grandy DK, Han JS (1997)
Bidirectional modulatory effect of orphanin FQ on morphine-induced
analgesia: antagonism in brain and potentiation in spinal cord of the
rat. Br J Pharmacol 120:676–680.
White WF, Heller AH (1982) Glycine receptor alteration in the mutant
mouse spastic. Nature 298:655–657.
Willis DW, Westlund KN, Carlton SM (1995) Pain. In: The rat nervous
system (Paxinos G, ed), pp 725–750. San Diego: Academic.
Xu IS, Hashemi M, Calo G, Regoli D, Wiesenfeld-Hallin Z, Xu XJ
(1999) Effects of intrathecal nocistatin on the flexor reflex and its
interaction with orphanin FQ nociceptin. NeuroReport 10:3681–3684.
Xu XJ, Hao JX, Wiesenfeld-Hallin Z (1996) Nociceptin or antinocicep-
tin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in
the rat. NeuroReport 7:2092–2094.
Yaksh TL, Malmberg AB (1994) Central pharmacology of nociceptive
transmission. In: Textbook of pain (Wall PD, Melzack R, eds), pp
165–200. Edinburgh: Churchill Livingstone.
Yaksh TL, Rudy TA (1977) Studies on the direct spinal action of nar-
cotics in the production of analgesia in the rat. J Pharmacol Exp Ther
202:411–428.
Yaksh TL, Hua XY, Kalcheva I, Nozaki-Taguchi N, Marsala M (1999)
The spinal biology in humans and animals of pain states generated by
persistent small afferent input. Proc Natl Acad Sci USA 96:7680–7686.
Yamamoto T, Sakashita Y (1999) Effect of nocistatin and its interaction
with nociceptin/orphanin FQ on the rat formalin test. Neurosci Lett
262:179–182.
Yamamoto T, Yaksh TL (1992) Comparison of the antinociceptive ef-
fects of pre- and posttreatment with intrathecal morphine and MK801,
an NMDA antagonist, on the formalin test in the rat. Anesthesiology
77:757–763.
Yamamoto T, Nozaki-Taguchi N, Kimura S (1997) Analgesic effect of
intrathecally administered nociceptin, an opioid receptor-like1 recep-
tor agonist, in the rat formalin test. Neuroscience 81:249–254.
Zamponi GW, Snutch TP (1998) Modulation of voltage-dependent cal-
cium channels by G proteins. Curr Opin Neurobiol 8:351–356.
Zieglga¨nsberger W, Herz A (1971) Changes of cutaneous receptive
fields of spino-cervical-tract neurones and other dorsal horn neurones
by microelectrophoretically administered amino acids. Exp Brain Res
13:111–126.
Zieglga¨nsberger W, To¨lle TR (1993) The pharmacology of pain signal-
ling. Curr Opin Neurobiol 3:611–618.
Zeilhofer et al. • Suppression of Spinal IPSCs by Nocistatin J. Neurosci., July 1, 2000, 20(13):4922–4929 4929
